As part of its continued expansion of services in Latin America, Marken has announced the planned September 1, 2011 launch of their Latin America regional depot network with facilities in Mexico City and Buenos Aires.
Marken is executing on its stated plan to build the most advanced, fit for purpose, pharmaceutical-focused clinical distribution network. This expanded network allows the company to build from its current industry-leading life sciences logistics platform, which serves over 6,000 investigator sites in 100 countries from its 24 global branch offices.
The Singapore facility is fully operational and has been successfully audited by several client companies. Additional depot facilities are planned in the Middle East, Europe, Asia and the Americas. This global network of direct-controlled, GMP-compliant depots allows maximum efficiency in the conduct of clinical trials, even in clinically-naïve regions.
“The expansion of these facilities is just one more step in supporting our clients’ needs in controlling the chain-of-custody of clinical trial assets.” said Wes Wheeler, Marken’s Chief Executive Officer. “Our goal is to be the premier provider of life sciences supply chain services. We are 100% focused on life sciences and will ensure that the strict requirements unique to the pharmaceutical and medical device communities are met, particularly with the recent focus on new regulatory documentation, strict temperature control and chain of custody.”
Each of Marken’s depots will also offer specimen kit distribution, collection, storage and management; and reverse logistics for dosage kits, drugs and equipment, including reconciliation and certified destruction. The Mexico and Argentina storage facilities include the full range of temperature control including controlled ambient, cold storage (2º-8ºC) and frozen (-20ºC) as well as secured drug store.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Real-World Data Show 99% Efficacy for Apretude in HIV Prevention with High Adherence, Reduced Stigma
October 16th 2024Real-world data presented at IDWeek 2024 show Apretude (cabotegravir long-acting) is more than 99% effective in preventing HIV infection, with high adherence rates, reduced stigma and anxiety, and broad acceptability.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.